Domvanalimab + Zimberelimab
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor, Unspecified, Adult
Conditions
Solid Tumor, Unspecified, Adult
Trial Timeline
Sep 12, 2018 → Jan 23, 2025
NCT ID
NCT03628677About Domvanalimab + Zimberelimab
Domvanalimab + Zimberelimab is a phase 1 stage product being developed by Gilead Sciences for Solid Tumor, Unspecified, Adult. The current trial status is completed. This product is registered under clinical trial identifier NCT03628677. Target conditions include Solid Tumor, Unspecified, Adult.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03628677 | Phase 1 | Completed |
Competing Products
20 competing products in Solid Tumor, Unspecified, Adult